Merck Serono Phase III Trial Extension For Safinamide In Parkinson’s Misses Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck will pursue lower dose in future clinical trials, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Merck Serono Initiates Phase III Trial Of Safinamide In Early Parkinson’s
Dosing and efficacy endpoint of the trial have been informed by earlier studies, including a failed Phase III.
Merck Serono Initiates Phase III Trial Of Safinamide In Early Parkinson’s
Dosing and efficacy endpoint of the trial have been informed by earlier studies, including a failed Phase III.
Merck Serono Drops Diabetes Investment After Portfolio Review
German biopharma seeks licensing partners for diabetes treatments now in development while firm focuses R&D on cancer, other indications.